Sanofi India Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/zaygyu3iv15svuogqxi5pwnb.pdf

Key Takeaways


Diabetes Portfolio & Insulin Strategy

Rodolfo Hrosz: "The brand has gone very fast. It's a second-generation basal insulin and we've seen that the market has an appetite for second generation, both in basal and also in the premium segment. So Lantus continues to grow on the wake of the NLEM price reduction and Toujeo continues to grow on the waves of this migration to second generation and more sophisticated basal insulin. So both have a very promising perspective and in fact both are performing well on their side, in their segment."

Consumer Healthcare Performance

Himanshu Bakshi: "When we look at quarter 4. Of course, there are some headwinds when it comes to the overall category performance. But the good news is that all our categories, all our brands continue to gain share in the market."

Product Launches & Pipeline


CATD Merger & Structural Changes


Exports & Manufacturing


Guidance & Commitments

CommitmentSpecificsTimeline
Soliqua launchEnter the pre-mix insulin segment with a differentiated productEnd of Q1 / beginning of Q2 FY25
Cetapin S launchLocal extension of existing brandEnd of Q1 FY25
CATD merger executionComplete separation of consumer healthcare businessQ2 FY25
Allegra introductionLaunch in consumer healthcare portfolioBy 2025
Lantus market sharePull additional share as price gap versus competitors has shrunk to near zeroOngoing, supported by Q4 volume growth of ~5%

Key Metrics

MetricQ3 FY24
Revenue₹525 cr, 12.6% growth as published, 10.6% comparable excluding NLEM price impact
Profit before tax growth+5.6%, excluding Soframycin divestment
Operating profit margin31%, up from 27% in Q3 FY23
Full-year revenue growth (comparable)5.4%, 1.2% as published
Full-year export growth+27%
Full-year opex change-6%
Full-year profit before tax margin31%, up from 26% in FY22
Dividend payout ratio65%, down from 85% last year, due to working capital build for warehouse address change
Diabetes portfolio EBIT contribution40% to 43%
Share of revenue under NLEM39% to 40%
Exports as share of total top line18% to 20%
Goa plant export share~30%
Lantus Q4 volume growth~5%
Opex savings from restructuring₹36 cr in fiscal year 2023
Diabetes awareness campaign reach>20 crore people in 2023